ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 274,48
-0,27%
Dow Jones
42 840,26
1,18%
DAX
19 884,75
-0,57%
Brent Oil
72,72
0,00%
Bitcoin
97 510,19
-0,25%
Registration Strip Icon for default Inscrivez-vous gratuitement pour obtenir des cotations en temps réel, des graphiques interactifs, un flux d'options en direct et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ

  6. Genenta Science SPA (GNTA) Cours

Genenta Science SPA

Genenta Science SPA (GNTA)

NASDAQ
5,01
-0,35
(-6,53%)
Fermé 21 Décembre 10:00PM
Retardé de 15 minutes
5,15
0,14
(2,79%)
Après les heures de négociation: 1:59AM
Retardé de 15 minutes

Outils de qualité professionnelle, pour des investisseurs individuels.

Premium

Statistiques et détails clés

Dernier
5,01
Prix Achat
5,02
Prix Vente
8,16
Volume échangé
4 556
5,01 Fourchette du Jour 5,39
0,00 Plage de 52 semaines 0,00
Cap du marché
91,267M
Clôture Veille
5,36
Ouverture
5,10
Dernière Transaction
527
@
5.01
Dernière heure de transaction
Volume financier
US$ 23 321
VWAP
5,1187
Volume moyen (3 m)
-
Actions en circulation
18 216 958
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-8,84
Bénéfice par action (BPA)
-0,58
Chiffre d'affairess
465k
Bénéfice net
-10,62M

À propos de Genenta Science SPA

Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affec... Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's product under development includes Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain, and TEMs -Immuno-Gene Therapy. Show more

Secteur
Health Practitioners, Nec
Industrie
Health Practitioners, Nec
Site Web
www.genenta.com
Siège social
Milan, Lombardy, Ita
Fondé
-
Genenta Science SPA est coté dans le secteur Health Practitioners de la NASDAQ avec le ticker GNTA. Le dernier cours de clôture d'Genenta Science était de US$5,36. Au cours de la dernière année, les actions de Genenta Science ont été négociées dans une fourchette de prix de US$ 0,00 à US$ 0,00.

Genenta Science compte actuellement 18 216 958 actions en circulation. La capitalisation boursière d'Genenta Science est de US$97,64 million. Genenta Science a un ratio cours/bénéfice (ratio PE) de -8.84.

GNTA Dernières nouvelles

Plus de nouvelles

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

il y a 15 heures
Edgar (US Regulatory)

Form 424B5 - Prospectus [Rule 424(b)(5)]

il y a 16 heures
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

13 Décembre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

14 Novembre 2024
Edgar (US Regulatory)

Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

29 Octobre 2024
Edgar (US Regulatory)

Genenta’s CEO to present at the U.S. Senate meeting on “Cross-Border Investments and Strategies in the Biotechnology Sector: A Transatlantic Perspective”

MILAN and NEW YORK, Oct. 23, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and in cell-based therapeutics, is pleased to announce that Pierluigi Paracchi...

23 Octobre 2024
GlobeNewswire Inc.

Genenta Secures Approval for Innovative Trial for Metastatic Renal Cell Cancer

MILAN and NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a pioneer in immuno-oncology and a leader in cell-based therapeutics, is pleased to announce that the...

02 Octobre 2024
GlobeNewswire Inc.

Genenta Welcomes New Directors John L. Cantello, Lauren H. Chung, Armon R. Sharei, and Todd Wider

MILAN, Italy and NEW YORK, May 06, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology company developing a cell-based platform harnessing the...

06 Mai 2024
GlobeNewswire Inc.

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]

12 Février 2024
Edgar (US Regulatory)

Genenta Demonstrated Reprogramming of the Tumor Microenvironment in GBM Patients, Paving the Way for Innovative Treatments of Solid Tumors

MILAN, Italy and NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Genenta Science (NASDAQ: GNTA), a clinical-stage immuno-oncology (I/O) company developing a cell-based platform harnessing the power...

08 Février 2024
GlobeNewswire Inc.
PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10000000DR
40000000DR
120000000DR
260000000DR
520000000DR
1560000000DR
2600000000DR

GNTA - Frequently Asked Questions (FAQ)

What is the current Genenta Science share price?
The current share price of Genenta Science is US$ 5,01
How many Genenta Science shares are in issue?
Genenta Science has 18 216 958 shares in issue
What is the market cap of Genenta Science?
The market capitalisation of Genenta Science is USD 97,64M
What is the 1 year trading range for Genenta Science share price?
Genenta Science has traded in the range of US$ 0,00 to US$ 0,00 during the past year
What is the PE ratio of Genenta Science?
The price to earnings ratio of Genenta Science is -8,84
What is the cash to sales ratio of Genenta Science?
The cash to sales ratio of Genenta Science is 201,96
What is the reporting currency for Genenta Science?
Genenta Science reports financial results in EUR
What is the latest annual turnover for Genenta Science?
The latest annual turnover of Genenta Science is EUR 465k
What is the latest annual profit for Genenta Science?
The latest annual profit of Genenta Science is EUR -10,62M
What is the registered address of Genenta Science?
The registered address for Genenta Science is VIA OLGETTINA, 58, 430 EAST 29TH STREET, MILAN, LOMBARDY, 20132
What is the Genenta Science website address?
The website address for Genenta Science is www.genenta.com
Which industry sector does Genenta Science operate in?
Genenta Science operates in the HEALTH PRACTITIONERS, NEC sector

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MYSZMy Size Inc
US$ 4,2001
(211,12%)
121,03M
NVNINVNI Group Ltd
US$ 8,26
(209,36%)
78,06M
TPICTPI Composites Inc
US$ 2,45
(100,82%)
34M
ICGIntchains Group Ltd
US$ 8,77
(88,60%)
527,94k
HSDTHelius Medical Technologies Inc
US$ 0,884851
(84,34%)
121,95M
CYNCYNGN Inc
US$ 0,4603
(-71,41%)
27,5M
MTEMMolecular Templates Inc
US$ 0,1502
(-57,09%)
8,63M
PRFXPainReform Ltd
US$ 5,15
(-53,85%)
2,84M
GALTGalectin Therapeutics Inc
US$ 1,03
(-48,50%)
8,58M
BCABBioAtla Inc
US$ 0,6923
(-41,82%)
5,96M
EDBLEdible Garden AG Inc
US$ 0,24
(65,06%)
354,33M
NVDANVIDIA Corporation
US$ 134,70
(3,08%)
310,19M
APTOAptose Biosciences Inc
US$ 0,28
(64,51%)
306,25M
TNXPTonix Pharmaceuticals Holding Corporation
US$ 0,606999
(6,49%)
293,22M
PLTRPalantir Technologies Inc
US$ 80,55
(8,54%)
281,23M

Forums

Afficher les forums
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

NASDAQ
GNTA
Genenta Science
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés